Nvidia Executives Sell $1 Billion Of Company Stock
Executives at Nvidia (NVDA) have been selling company stock as the share price hits new all-time highs. Filings with the U.S. Securities and Exchange Commission (SEC) show that senior executives at chipmaker Nvidia have sold more than $1 billion U.S. in stock over the last year.About half the amount sold ($500 million U.S.) has occurred in June of this year as Nvidia’s share price hit new record highs. The stock is up more than 17% this year and up 44% from its April lows despite ongoing concerns over potential curbs on microchip and semiconductor sales to China.The recent sales have included Nvidia’s chief executive officer (CEO) Jensen Huang, who sold about $15 million U.S. worth of shares as part of his more than $900 million U.S. plan to sell up to six million shares through the end of this year. In 2024, Huang sold more than $700 million U.S. in Nvidia shares as part of a prearranged plan. His net worth is estimated at about $140 billion U.S.Nvidia’s stock recently hit an all-time high of $158.71 U.S. per share on a split adjusted basis. The company now has a market capitalization of $3.85 trillion U.S. and is the largest publicly traded firm in the world. The recent share sales by company executives at Nvidia appears to have been prompted by the stock rising above $150 U.S. per share. Senior executives at publicly traded companies often have pre-set plans in place to sell shares when they reach a certain price or when other milestones are achieved. NVDA stock is currently trading at $157.75 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


